DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies November 27, 2020 08:00 ET | Source: Sorrento Therapeutics, Inc. Initial funding of up to $34 million for the project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody [...]

Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo Production of Antibody Therapeutics in Patients September 2, 2020 at 9:00 AM EDT Download PDF SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: [...]

For Immediate Release March 23, 2020     SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19 Collaboration to leverage synergies between Monoclonal Antibody and Non-Viral Gene Delivery Platforms SAN DIEGO and BOSTON, March 23, 2020 /GlobeNewswire/ -- In response to the government call for rapidly deployable countermeasures, [...]

CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced the appointment of John T. Potts, MD, DSc, to its Board of Directors. Dr. Potts' distinguished, five-decade career in healthcare and the life sciences spans medical [...]

SmartPharm Therapeutics Announces Presentation at the 2019 BIO Investor Forum CAMBRIDGE, Mass., Oct. 16, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, Chief Executive Officer, will present at the 2019 BIO [...]

SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer CAMBRIDGE, Mass. – June 25, 2019 – SmartPharm Therapeutics, a pre-clinical stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, has been appointed Chief Executive Officer. Dr. [...]